Professor of Medicine, Physiology, and Cell Biology at the Ohio State University, USA
Professor of Medicine, Physiology, and Cell Biology at the Ohio State University, USA
Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts, following which he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of Colorado Health Sciences Center.
He previously held leadership positions at the University of Colorado, the University of Cincinnati, the University of Kentucky, and the Ohio State University.
At Ohio State, Dr. Abraham held several leadership positions including an Associate Dean position, managing the College of Medicine’s non-cancer clinical and translational research portfolio of more than 1,800 studies.
As Division Director at Ohio State, Dr. Abraham developed one of the largest and most successful academic programs of Cardiovascular Medicine in the U.S.
Clinically, Dr. Abraham is board certified in Internal Medicine and Advanced Heart Failure and Transplant Cardiology. He spends the majority of his clinical time managing heart failure patients in the outpatient setting. Dr. Abraham has been recognized as one of the “Best Doctors in America” for sixteen consecutive years and is ranked among the top 10% of physicians nationally for patient satisfaction.
Dr. Abraham’s research activities focus on elucidating basic mechanisms in heart failure and on clinical drug and device trials in heart failure. Dr. Abraham has received grants from the National Institutes of Health (NIH) including current NIH funding, the American College of Cardiology, and the Aetna Quality Care Foundation.
He has made major contributions to advancing clinical science and patient care in heart failure in at least three areas: device development in heart failure and related co-morbidities; neurohormonal therapies in heart failure; and acute heart failure and renal dysfunction complicating heart failure.
Dr. Abraham has participated in all clinical and regulatory phases of new drug and device development from pre-clinical evaluation to Pre-Market Approval (PMA) and New Drug Application (NDA) submission and approval. He has extensive experience interacting with the U.S. Food and Drug Administration and as a consultant to various CE Marking Notified Bodies of the European Union. His work has led to the approval and adoption of several new therapies for heart failure, including beta-blockers, natriuretic peptides, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamic monitoring, transvenous phrenic nerve stimulation, cardiac contractility modulation, transcatheter mitral valve repair, and baroreflex activation therapy.
Dr. Abraham has authored more than 1,000 original papers, abstracts, book chapters, and review articles. His work has been published in high impact journals, including The New England Journal of Medicine, The Lancet, the Journal of the American Medical Association, Circulation, the European Heart Journal, and the Journal of the American College of Cardiology.
Dr. Abraham has co-authored national heart failure practice guidelines and co-edited a leading textbook on heart failure entitled Heart Failure: A Practical Approach to Treatment and serves as series editor for the Color Atlas and Synopsis of Cardiovascular Medicine.
Dr. Abraham serves on the editorial boards of several major journals. Annually since 2014, he was named to the Clarivate Analytics (formerly Thomson Reuters) Highly Cited Researchers list and as one of The World’s Most Influential Scientific Minds. In 2017, he received the Distinguished Scientist Award (Clinical Domain) from the American College of Cardiology.